Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Post registration observational program for patients with locally recurrent or metastatic breast cancer who receive bevacizumab (Avastin) in combination with paclitaxel for the first-line treatment

Trial Profile

Post registration observational program for patients with locally recurrent or metastatic breast cancer who receive bevacizumab (Avastin) in combination with paclitaxel for the first-line treatment

Status: Withdrawn prior to enrolment
Phase of Trial: Phase IV

Latest Information Update: 20 Oct 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bevacizumab (Primary) ; Paclitaxel (Primary)
  • Indications Advanced breast cancer; HER2 negative breast cancer; Non-small cell lung cancer
  • Focus Adverse reactions
  • Acronyms AVATAX
  • Sponsors Roche
  • Most Recent Events

    • 14 Sep 2021 Results (n=314; From January 2010 to February 2020) assessing safety and efficacy of the combination paclitaxel-bevacizumab in metastatic non-squamous non-small cell lung cancer as second-line therapy, presented at the 2021 World Conference on Lung Cancer.
    • 28 Nov 2011 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 15 Jul 2010 Planned end date changed from 1 Jun 2011 to 1 Dec 2012 as reported by ClinicalTrials.gov.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top